Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma‑associated mRNAs in high‑risk neuroblastoma patients

Uemura,Suguru; Lin,Kyaw San; Mon Thwin,Khin Kyae; Nakatani,Naoko; Ishida,Toshiaki; Yamamoto,Nobuyuki; Tamura,Akihiro; Saito,Atsuro; Mori,Takeshi; Hasegawa,Daiichiro; Kosaka,Yoshiyuki; Nino,Nanako; Nagano,China; Takafuji,Satoru; Iijima,Kazumoto; Nishimura,Noriyuki

doi:10.3892/mco.2021.2299

Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma‑associated mRNAs in high‑risk neuroblastoma patients

Authors:
- Suguru Uemura
- Kyaw San Lin
- Khin Kyae Mon Thwin
- Naoko Nakatani
- Toshiaki Ishida
- Nobuyuki Yamamoto
- Akihiro Tamura
- Atsuro Saito
- Takeshi Mori
- Daiichiro Hasegawa
- Yoshiyuki Kosaka
- Nanako Nino
- China Nagano
- Satoru Takafuji
- Kazumoto Iijima
- Noriyuki Nishimura
View Affiliations

Affiliations: Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Hyogo 650‑0017, Japan, Department of Hematology and Oncology, Kobe Children's Hospital, Kobe, Hyogo 650‑0047, Japan, Department of Public Health, Kobe University Graduate School of Health Science, Kobe, Hyogo 654‑0142, Japan
Published online on: May 19, 2021 https://doi.org/10.3892/mco.2021.2299
Article Number: 137

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vanillylmandelic acid (VMA), homovanillic acid (HVA), neuron‑specific enolase (NSE) and lactate dehydrogenase (LDH) are classical tumor markers and are used as standard clinical evaluations for patients with neuroblastoma (NB). Minimal residual disease (MRD) can be monitored by quantifying several sets of NB‑associated mRNAs in the bone marrow (BM) and peripheral blood (PB) of patients with NB. Although MRD in BM and PB has been revealed to be a strong prognostic factor that is independent of standard clinical evaluations, its interrelation with tumor markers remains uncharacterized. The present study determined the levels of tumor markers (VMA, HVA, NSE and LDH) and MRD (BM‑MRD and PB‑MRD) in 133 pairs of concurrently collected BM, PB and urine samples from 19 patients with high‑risk NB. The patients were evaluated during the entire course of treatment, which included 10 diagnoses, 32 treatments, 36 post‑treatment, 9 relapses and 46 post‑relapse sample pairs. The level of BM‑MRD and PB‑MRD was determined by quantifying 7 NB‑mRNAs (collapsin response mediator protein 1, dopamine beta‑hydroxylase, dopa decarboxylase, growth‑associated protein 43, ISL LIM homeobox 1, pairedlike homeobox 2b and tyrosine hydroxylase) using droplet digital PCR. In overall sample pairs, tumor markers (VMA, HVA, NSE and LDH) demonstrated weak but significant correlations (P<0.011) with BM‑MRD and PB‑MRD. In subgroups according to each patient evaluation, the degree of correlation between tumor markers and MRD became stronger in patients with adrenal gland tumors, BM metastasis at diagnosis and relapse/regrowth compared with overall sample pairs. In contrast, tumor markers demonstrated variable correlations with MRD in subgroups according to each sample evaluation (BM infiltration at sampling, collection time point and disease status). The results suggested that tumor markers may demonstrate limited correlation with MRD in patients with high‑risk NB.

View Figures

View References

1	Brodeur GM: Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.PubMed/NCBI View Article : Google Scholar
2	Maris JM, Hogarty MD, Bagatell R and Cohn SL: Neuroblastoma. Lancet. 369:2106–2120. 2007.PubMed/NCBI View Article : Google Scholar
3	Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, et al: Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 33:3008–3017. 2015.PubMed/NCBI View Article : Google Scholar
4	Morgenstern DA, Potschger U, Moreno L, Papadakis V, Owens C, Ash S, Pasqualini C, Luksch R, Garaventa A, Canete A, et al: Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study. Pediatr Blood Cancer. 65(e27363)2018.PubMed/NCBI View Article : Google Scholar
5	Smith V and Foster J: High-risk neuroblastoma treatment review. Children (Basel). 5(114)2018.PubMed/NCBI View Article : Google Scholar
6	MacFarland S and Bagatell R: Advances in neuroblastoma therapy. Curr Opin Pediatr. 31:14–20. 2019.PubMed/NCBI View Article : Google Scholar
7	Maris JM: Recent advances in neuroblastoma. N Engl J Med. 362:2202–2211. 2010.PubMed/NCBI View Article : Google Scholar
8	Tolbert VP and Matthay KK: Neuroblastoma: Clinical and biological approach to risk stratification and treatment. Cell Tissue Res. 372:195–209. 2018.PubMed/NCBI View Article : Google Scholar
9	Uemura S, Ishida T, Thwin KKM, Yamamoto N, Tamura A, Kishimoto K, Hasegawa D, Kosaka Y, Nino N, Lin KS, et al: Dynamics of minimal residual disease in neuroblastoma patients. Front Oncol. 9(455)2019.PubMed/NCBI View Article : Google Scholar
10	London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T and Matthay KK: Clinical and biologic features predictive of survival after relapse of neuroblastoma: A report from the International Neuroblastoma Risk Group project. J Clin Oncol. 29:3286–3292. 2011.PubMed/NCBI View Article : Google Scholar
11	Riley RD: A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 10:4–12. 2004.PubMed/NCBI View Article : Google Scholar
12	Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI, et al: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 6:1874–1881. 1988.PubMed/NCBI View Article : Google Scholar
13	Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 11:1466–1477. 1993.PubMed/NCBI View Article : Google Scholar
14	Simon T, Hero B, Hunneman DH and Berthold F: Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer. 39:1899–1903. 2003.PubMed/NCBI View Article : Google Scholar
15	Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, et al: The international neuroblastoma risk group (INRG) classification system: An INRG task force report. J Clin Oncol. 27:289–297. 2009.PubMed/NCBI View Article : Google Scholar
16	Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, et al: Revisions to the international neuroblastoma response criteria: A consensus statement from the national cancer institute clinical trials planning meeting. J Clin Oncol. 35:2580–2587. 2017.PubMed/NCBI View Article : Google Scholar
17	Bozzi F, Gambirasio F, Luksch R, Collini P, Brando B and Fossati-Bellani F: Detecting CD56⁺/NB84⁺/CD45^-immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry. Anticancer Res. 26:3281–3287. 2006.PubMed/NCBI
18	Popov A, Druy A, Shorikov E, Verzhbitskaya T, Solodovnikov A, Saveliev L, Tytgat GAM, Tsaur G and Fechina L: Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma. J Cancer Res Clin Oncol. 145:535–542. 2019.PubMed/NCBI View Article : Google Scholar
19	Stutterheim J, Ichou FA, den Ouden E, Versteeg R, Caron HN, Tytgat GA and van der Schoot CE: Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma. Clin Cancer Res. 18:808–814. 2012.PubMed/NCBI View Article : Google Scholar
20	Beiske K, Ambros PF, Burchill SA, Cheung IY and Swerts K: Detecting minimal residual disease in neuroblastoma patients-the present state of the art. Cancer Lett. 228:229–240. 2005.PubMed/NCBI View Article : Google Scholar
21	Brownhill SC and Burchill SA: PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers-Focus on neuroblastoma. Pract Lab Med. 7:41–44. 2017.PubMed/NCBI View Article : Google Scholar
22	Burchill SA, Bradbury FM, Smith B, Lewis IJ and Selby P: Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Int J Cancer. 57:671–675. 1994.PubMed/NCBI View Article : Google Scholar
23	Viprey VF, Corrias MV, Kågedal B, Oltra S, Swerts K, Vicha A, Ladenstein R and Burchill SA: Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: Quality assurance on behalf of SIOPEN-R-NET. Eur J Cancer. 43:341–350. 2007.PubMed/NCBI View Article : Google Scholar
24	Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, et al: PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol. 26:5443–5449. 2008.PubMed/NCBI View Article : Google Scholar
25	Stutterheim J, Zappeij-Kannegieter L, Versteeg R, Caron HN, van der Schoot CE and Tytgat GAM: The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer. 47:1193–1202. 2011.PubMed/NCBI View Article : Google Scholar
26	Viprey VF, Gregory WM, Corrias MV, Tchirkov A, Swerts K, Vicha A, Dallorso S, Brock P, Luksch R, Valteau-Couanet D, et al: Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: A European HR-NBL1/SIOPEN study. J Clin Oncol. 32:1074–1083. 2014.PubMed/NCBI View Article : Google Scholar
27	Cheung NK, Ostrovnaya I, Kuk D and Cheung IY: Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy. J Clin Oncol. 33:755–763. 2015.PubMed/NCBI View Article : Google Scholar
28	Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, et al: Expression of five neuroblastoma genes in bone marrow or blood of patients with relapsed/refractory neuroblastoma provides a new biomarker for disease and prognosis. Clin Cancer Res. 23:5374–5383. 2017.PubMed/NCBI View Article : Google Scholar
29	Akobeng AK: Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr. 96:644–647. 2007.PubMed/NCBI View Article : Google Scholar
30	Hartomo TB, Kozaki A, Hasegawa D, Van Huyen Pham T, Yamamoto N, Saitoh A, Ishida T, Kawasaki K, Kosaka Y, Ohashi H, et al: Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells. Oncol Rep. 29:1629–1636. 2013.PubMed/NCBI View Article : Google Scholar
31	Hirase S, Saitoh A, Hartomo TB, Kozaki A, Yanai T, Hasegawa D, Kawasaki K, Kosaka Y, Matsuo M, Yamamoto N, et al: Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients. Oncol Lett. 12:1119–1123. 2016.PubMed/NCBI View Article : Google Scholar
32	Thwin KKM, Ishida T, Uemura S, Yamamoto N, Lin KS, Tamura A, Kozaki A, Saito A, Kishimoto K, Mori T, et al: Level of seven neuroblastoma-associated mRNAs detected by droplet digital PCR is associated with tumor relapse/regrowth of high-risk neuroblastoma patients. J Mol Diagn. 22:236–246. 2020.PubMed/NCBI View Article : Google Scholar
33	Weinstein JL, Katzenstein HM and Cohn SL: Advances in the diagnosis and treatment of neuroblastoma. Oncologist. 8:278–292. 2003.PubMed/NCBI View Article : Google Scholar
34	Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GA, Brock PR, Haber M, Park JR and Berthold F: Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer. 123:1095–1105. 2017.PubMed/NCBI View Article : Google Scholar
35	Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, et al: The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 55:611–622. 2009.PubMed/NCBI View Article : Google Scholar
36	Huggett JF, Foy CA, Benes V, Emslie K, Garson JA, Haynes R, Hellemans J, Kubista M, Mueller RD, Nolan T, et al: The digital MIQE guidelines: Minimum information for publication of quantitative digital PCR experiments. Clin Chem. 59:892–902. 2013.PubMed/NCBI View Article : Google Scholar
37	Schober P, Boer C and Schwarte LA: Correlation coefficients. Anesth Analg. 126:1763–1768. 2018.PubMed/NCBI View Article : Google Scholar
38	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013.PubMed/NCBI View Article : Google Scholar
39	Moroz V, Machin D, Hero B, Ladenstein R, Berthold F, Kao P, Obeng Y, Pearson ADJ, Cohn SL and London WB: The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 67(e28359)2020.PubMed/NCBI View Article : Google Scholar